BioSpace News Archive

The safety profile of Cosentyx was in line with the known safety profile.

Lumosa Therapeutics and Skyline Vet Pharma today announced a licensing agreement for Lumosa’s CS011.

Context made a one-time payment to Arno Therapeutics in exchange for the worldwide rights to Apristor.

Marken announced today the opening of a new Kit Building Center in Shanghai, the company’s third location in addition to Hamburg and Singapore.

Replicel Life Sciences is pleased to announce it has signed a Binding Term Sheet with YOFOTO to form a strategic partnership in Greater China.

The primary endpoints for the study were fully achieved and DAV132 showed an excellent tolerability profile.

Gamida Cell today announced the initiation of a phase I study evaluating its proprietary NAM-expanded natural killer cells (NAM-NK Cells) in patients with relapsed or refractory CD20+ non-Hodgkin lymphoma (NHL) and multiple myeloma.

Aerie announced the appointments of Nils Hauptmann as Director of Regulatory Affairs and Pharmacovigilance, reporting to Cindy Martin, Aerie’s Vice President of Regulatory, and Tim Swan as Director of Sales and Transparency Operations, reporting to Gerry McKenzie, Aerie’s Vice President of Commercial Operations.

Cellect announced that it has signed an agreement with the Hadassah Medical Center to conduct clinical trials on cancer patients in Cellect’s ongoing Phase I/II study.

RXi Pharma outlined its 2018 business strategy during a webcast presentation at the Biotech Showcase conference which brought together over 3,500 life science decision makers and investors from over 50 countries to collaborate and discuss industry trends.